欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > CellCycle/Checkpoint > Afuresertib (hydrochloride)

浏览历史

S81822

Afuresertib (hydrochloride)

源叶(MedMol) 96%
  • 英文名:
  • Afuresertib (hydrochloride)
  • 别名:
  • Afuresertib HCl; Afuresertib hydrochloride; UNII-0FC27E442O;
  • CAS号:
  • 1047645-82-8
  • 分子式:
  • C18H18Cl3FN4OS
  • 分子量:
  • 463.7841
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S81822-5mg 96% ¥930.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S81822-10mg 96% ¥1400.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S81822-50mg 96% ¥3900.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively
  • 靶点: Akt1:0.08 nM (Ki);Akt2:2 nM (Ki);Akt3;2.6 nM (Ki);Akt1 E17K mutant:0.2 nM (IC50);PKCη:210 nM (IC50);PKC-βI;430 nM (IC50);ROCK:100 nM (IC50);PKCθ:510 nM (IC50);ROCK; Akt; PKC
  • 体外研究:
    Afuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase. Western blotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response
  • 体内研究:
    Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts
  • 参考文献:
    1. Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. 2. Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880
  • 溶解性: soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.156 ml 10.781 ml 21.562 ml
    5 mM 0.431 ml 2.156 ml 4.312 ml
    10 mM 0.216 ml 1.078 ml 2.156 ml
    50 mM 0.043 ml 0.216 ml 0.431 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。